-- ヒューマンウェル・ヘルスケア（SHA:600079）傘下の医薬品開発会社が、急性疼痛治療薬RFUS-188の臨床試験開始について、中国の規制当局の承認を取得したと、木曜日に上海証券取引所に提出した書類で明らかにした。 この薬剤は、血液脳関門を通過することなく末梢のκオピオイド受容体を標的とするため、従来のオピオイドに見られる依存性、呼吸抑制、その他の重篤な副作用を解消できる可能性がある。 同社の株価は、直近の取引で1%下落した。
Related Articles
International
Swiss Jobless Rate Inches Down to 3% in April
Switzerland's unemployment rate stood at 3% in April, down from 3.1% in the previous month, according to data from the State Secretariat for Economic Affairs published Thursday.At the end of April, 142,902 individuals were registered as unemployed, down by 3,353 from a month ago.
$^SSMI
Asia
Pansar Unit Bags MYR235 Million Water Treatment Plant Upgradation Deal
Pansar (KLSE:PANSAR) unit Perbena Emas secured a contract worth 234.9 million ringgit from Sarawak's Rural Water Supply Department (JBALB) to upgrade the Kaki Wong Water Treatment Plant, according to a Wednesday Malaysian bourse filing.Shares slid 1% in Thursday's midday trade.The project covers the construction of a new 30 MLD water treatment plant, a raw water intake system, booster pump stations, pipelines, a reservoir, and supporting buildings, including staff quarters. It also involves upgrading and refurbishing the existing plant and administrative facilities.Deal work is set to begin in June this year, with completion targeted in 30 months, it said.
$KLSE:PANSAR
International
China's May Day Holiday Consumption Up 14%
China's consumption-related industries saw sales revenue jump 14% year on year during the May Day holiday, according to the State Taxation Administration.Tourism and entertainment services rose 21%, while cultural services climbed 42% and sports services surged 44%.Health services jumped 40%, with health consultation services up 41%. Catering revenue rose 31%, driven by bars and teahouses at 52% and snack services at 42%.
$^SSEC$^SZSE